Particula | $5,500,000 | (May 1, 2025)
Stimuler | $3,750,000 | (May 1, 2025)
SpriveApp | $7,300,000 | (May 1, 2025)
Certified by Founder
Lodge
RheumaGen
start up
United States
- Denver, Colorado
- 10/01/2025
- Series A
- $15,000,000
RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure major autoimmune diseases at their source. RheumaGen focuses on editing the human leukocyte antigen (HLA), or “immune gene,” to develop one-time, curative cell and gene therapies. RheumaGen is headquartered in Aurora, Colorado. For more information, please visit rheumagen.com.
- Industry Biotechnology Research
- Website https://www.rheumagen.com/
- LinkedIn https://www.linkedin.com/company/rheumagen/
Manifest | $15,000,000 | (May 1, 2025)
Spark Biomedical Inc | $15,000,000 | (May 1, 2025)
Queens Carbon | $10,000,000 | (May 1, 2025)
Noma Therapy | $4,250,000 | (May 1, 2025)
Persona | $200,000,000 | (May 1, 2025)
Nuvo | $45,000,000 | (May 1, 2025)
Pallie | $2,000,000 | (May 1, 2025)
Faye(US) | $2,500,000 | (May 1, 2025)
Structify | $4,100,000 | (May 1, 2025)